By Felipe Bijit and Stefan Larsen
Psychedemics Corporation (PMD), as might be expected from a micro-cap stock, has what we might consider a divided personality. On the one hand, the company offers the possibility of returns through its unique technology allowing for organic growth. On the other hand, the firm is threatened by international, legal, competitive and liquidity risks. While we account for the risk-reward dichotomy throughout our analysis, we feel that the risks outweigh the rewards and ultimately do not recommend buying the stock.
Introduction
Psychemedics Corporation provides testing services for the